Ferguson Enterprises Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Ferguson Enterprises Inc. Common Stock trades at $222 (market cap $43.11B), while Twist Bioscience Corp trades at $145.29 (market cap $10.03B). The key difference: Ferguson Enterprises Inc. Common Stock is far larger — about 4.3× Twist Bioscience Corp's market cap, and Ferguson Enterprises Inc. Common Stock pays a 1.6% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferguson Enterprises Inc. Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| FERG | TWST | |
|---|---|---|
Market Cap | $43.11B | $10.03B |
Volume | 945,793 | 1,528,940 |
Sector | Industrials | Health |
52-Week High | $267.71 | $205.00 |
52-Week Low | $214.26 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $49.56B | $9.96B |
Dividend Yield | 1.6% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ferguson Enterprises, Inc. distributes plumbing, HVAC, waterworks, and related building products to professional contractors, builders, and facility managers across North America, operating through branches, showrooms, and digital commerce.
Read more on FERG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →